Intermediate dose (baclofen, naltrexone, sorbitol)	Placebo	Charcot Marie Tooth Neuropathy Score	-1	-1	CMTNS <TAB> 2.6 (17.5) <TAB> 0.5 (23.2) <TAB> −3.1 (16.0) <TAB> 7.7 (18.4) <TAB> −2.6 (−11.9;7.6) <TAB> 0.67 <TAB> −3.1 (−11.0;5.4) <TAB> 0.74
High dose (baclofen, naltrexone, sorbitol)	Placebo	Overall Neuropathy Limitations Scale improvement	1775	2142	The highest dose (HD) showed consistent evidence of improvement beyond stabilization. CMTNS and ONLS, with a significant improvement of respectively of 8% (0.4% - 16.2%) and 12.1% (2% - 23.2%) in the HD group versus the pool of all other groups, appear to be the most sensitive clinical endpoints to treatment despite their quasi-stability over one year under Placebo
High dose (baclofen, naltrexone, sorbitol)	Placebo	Sensitive Conduction Velocity 	-1	-1	0.42 <TAB> 0.01*
High dose (baclofen, naltrexone, sorbitol)	Placebo	Overall Neuropathy Limitations Scale improvement	-1	-1	For most of the efficacy outcomes, the best improvement was observed in the HD group (CMTNS, ONLS, 6MWT, 9HPT, Grip, MA, MCV and SCV)
Intermediate dose (baclofen, naltrexone, sorbitol)	Placebo	Charcot Marie Tooth Neuropathy Score	-1	-1	<td><NEWLINE> <NEWLINE><bold>CMTNS</bold><NEWLINE> <NEWLINE></td><td>2.6 (17.5)</td><td>0.5 (23.2)</td><td>−3.1 (16.0)</td><td><NEWLINE> <NEWLINE><bold>7.7 (18.4)</bold><NEWLINE> <NEWLINE></td><td>−2.6 (−11.9;7.6)</td><td>0.67</td><td>−3.1 (−11.0;5.4)</td><td>0.74</td><td>5.5 (−3.4;15.2)</td><td>0.16</td><td>0.54</td><td>0.30</td>
High dose (baclofen, naltrexone, sorbitol)	Placebo	Distal Motor Latency improvement	-1	-1	0.21 <TAB> 0.035*
Low dose (baclofen, naltrexone, sorbitol)	Placebo	Distal Motor Latency improvement	-1	-1	DML (ms) <TAB> 0.4 (8.8) <TAB> 3.6 (21.7) <TAB> 15.3 (35.8) <TAB> 8.4 (21.7) <TAB> 3.4 (−4.3;11.7) <TAB> 0.24
High dose (baclofen, naltrexone, sorbitol)	Placebo	Sensitive Conduction Velocity 	28419	28625	DML was significantly decreased in the HD group when compared to Placebo (8%, P = 0.038), and SCV was significantly increased in HD when compared to Placebo (26.6%, P = 3.70×10−4) and PLI (20.1%, P = 0.03).
Low dose (baclofen, naltrexone, sorbitol)	Placebo	Charcot Marie Tooth Neuropathy Score	-1	-1	<td><NEWLINE> <NEWLINE><bold>CMTNS</bold><NEWLINE> <NEWLINE></td><td>2.6 (17.5)</td><td>0.5 (23.2)</td><td>−3.1 (16.0)</td><td><NEWLINE> <NEWLINE><bold>7.7 (18.4)</bold><NEWLINE> <NEWLINE></td><td>−2.6 (−11.9;7.6)</td><td>0.67</td><td>−3.1 (−11.0;5.4)</td><td>0.74</td><td>5.5 (−3.4;15.2)</td><td>0.16</td><td>0.54</td><td>0.30</td>
